Skip to main content

Table 1 Patient demographics and clinical data

From: Transcriptomic and metabolomic insights into neutrophil activity in COPD complicated by metabolic syndrome

 

COPD–MS (n = 12)

COPD (n = 18)

P Value

Gender, M/F

8/4

16/2

 

Age (years)

77.00 (75.50,79.00)

73.50 (70.00,77.00)

0.059

Cost (yuan)

16,727 (12,850,18,447)

12,519 (10,641,14,767)

0.022

AE

2.00 (1.50,3.00)

1.00 (1.00,2.00)

0.095

BMI (kg/m2)

23.89 ± 2.93

21.24 ± 3.18

0.015

Waistline (cm)

89.17 ± 9.41

77.56 ± 6.99

0.001

FEV1/FVC

49.88 ± 11.77

49.51 ± 10.29

0.928

FEV1%

51.10 ± 23.85

50.34 ± 22.28

0.931

Blood Glucose (mmol/L)

6.09 (5.13,7.93)

5.02 (4.53,5.51)

0.028

TC (mmol/L)

5.14 (3.44,5.65)

3.76 (3.65,4.45)

0.305

TG (mmol/L)

1.10 (0.75,1.71)

0.69 (0.59,0.80)

0.007

LDL cholesterol (mmol/L)

2.65 (2.08,3.43)

1.96 (1.98,2.98)

0.031

HDL cholesterol (mmol/L)

1.01 ± 0.48

1.62 ± 0.38

0.001

CLU (mmol/L)

6.32 (5.01,7.93)

5.06 (4.50,5.99)

0.146

CRP (mg/L)

25.48 (8.44,56.50)

9.21 (2.03,19.87)

0.043

PCT (ng/mL)

0.08 (0.06,0.18)

0.04 (0.02,0.09)

0.124

ESR (mm/H)

57.5 (41,115)

22 (12,41)

0.001

WBC (*109/L)

9.22 ± 2.05

6.82 ± 1.84

0.002

Neu (*109/L)

6.29 (5.87,7.77)

4.88 (3.96,6.21)

0.008

TP (g/L)

62.44 ± 7.26

61.98 ± 5.32

0.843

ALB (g/L)

34.47 ± 4.20

35.08 ± 3.33

0.658

GLO (g/L)

25.80 (22.25,30.10)

26.95 (23.60,29.20)

0.602

Tbil (umol/l)

12.53 (9.67,14.73)

10.16 (8.62,16.14)

0.391

ALT (U/L)

19.45 (12.56,14.73)

12.53 (9.67,14.73)

0.079

AST (U/L)

20.10 (16.50,32.40)

19.20 (15.30,31.30)

0.692

D-dimer (mg)

0.66 (0.39,2.43)

0.37 (0.23,0.52)

0.025

BNP (ng/L)

40.50 (22.95,422.85)

60.15 (10.00,213.70)

0.415

Cr (umol/L)

87.88 ± 14.61

74.41 ± 13.83

0.016

UA (umol/L)

358.56 ± 94.75

282.09 ± 63.34

0.013

BP (mmHg)

154.25 ± 10.21/96.36 ± 5.12

114.69 ± 9.73/74.62 ± 6.76

0.001

  1. AE: Respiratory symptoms suddenly deteriorate beyond the usual variations, with the main symptoms being increased difficulty in breathing, often accompanied by wheezing, chest tightness, worsening cough, increased sputum production, changes in sputum color and/or viscosity, and fever
  2. AE adverse events, BMI body mass index, FEV1/FVC forced expiratory volume in 1 s/forced vital capacity, FEV1% forced expiratory volume 1 s as a percentage of predicted, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CLU clusterin, CRP C-reactive protein, PCT procalcitonin, ESR erythrocyte sedimentation rate, WBC white blood cell count, NEU neutrophil count, TP total plasma protein, ALB albumin, GLO globulins, Tbil total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, BNP B-type natriuretic peptide, Cr creatinine, UA uric acid